Skip to content

Who we are

Scailyte is a spin off of the ETH Zurich, founded in 2017 by visionary scientists who believed in the power of single-cell omics and AI to revolutionize precision medicine. Our world-class founding team keeps us at the cutting edge of science and technology.

Peter Nestorov -We have a world-class founding team that keeps us at the cutting edge of science and technology
Peter Nestorov -We have a world-class founding team that keeps us at the cutting edge of science and technology
Manfred Claassen -We have a world-class founding team that keeps us at the cutting edge of science and technology

What we do

Scailyte has developed a unique and powerful biomarker discovery approach, which uses a proprietary AI-driven software and single-cell omics data to significantly de-risk clinical trials and maximize patient benefit in immuno-oncology.

The problem

Clinical trials fail

Clinical trials fail over 90% of the time and the key reason is failure to demonstrate clinical efficacy. At the same time approved drugs in oncology work in only a fraction of patients (in the best case up to 50% of patients respond to a treatment). The heterogeneity of patient and disease biology is poorly captured by conventional biomarker approaches, leading to inappropriate treatment, poor patient outcomes and ultimately millions of patients 

 

The solution

The solution: to capture the complexity of cancer biology and enable patient stratification that matches the right patient to the right drug, we deploy deep molecular profiling with cellular resolution (single-cell omics), extract clinically-relevant insights and translate them into medical products. 

Scailyte’s unique application of AI to single-cell omics fully leverages its potential and will revolutionize biomedical discovery and clinical R&D. Our approach has been applied in multiple research partnerships and the results published in top journals.
Currently partnering with 3 industry players, and we have previously partnered with 7 pharma & biotech companies.
We have successfully translated several biomarkers derived from single-cell omics into clinical assays outperforming gold standards. We have 6 patents pending on biomarker signatures.

Scailyte’s unique application of AI to single-cell omics fully leverages its potential and will revolutionize biomedical discovery and clinical R&D. Our approach has been applied in multiple research partnerships and the results published in top journals.

Currently partnering with 3 industry players, and we have previously partnered with 7 pharma & biotech companies.

We discover biomarkers that are up to 80% more sensitive than those found with conventional computational approaches.

We have successfully translated several biomarkers derived from single-cell omics into clinical assays outperforming gold standards. We have 6 patents pending on biomarker signatures.

To scale commercially and become a leader in biomarker discovery and companion diagnostics in the immuno-oncology space, we are fundraising.